XM does not provide services to residents of the United States of America.
G
G

GlobalPayments

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

U.S. CME Group, Ingersoll Rand, Winnebago Industries

U.S. RESEARCH ROUNDUP-CME Group, Ingersoll Rand, Winnebago Industries June 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CME Group, Ingersoll Rand and Winnebago Industries, on Friday. HIGHLIGHTS * CME Group Inc CME.O : JP Morgan cuts to underweight from neutral * Ingersoll Rand Inc IR.N : Jefferies resumes coverage with buy rating; PT $110 * Nike Inc NKE.N : Oppenheimer raises to outperform from perform * Sarept
A
A
C
K
M
M
N
N
G
I
A
D

U.S. BioNTech, Honeywell International, Klaviyo

U.S. RESEARCH ROUNDUP-BioNTech, Honeywell International, Klaviyo June 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Biontech, Honeywell International and Klaviyo, on Wednesday. HIGHLIGHTS * BioNTech SE BNTX.O : JP Morgan raises target price to $94 from $90 * Honeywell International Inc HON.O : HSBC raises target price to $235 from $200 * Klaviyo Inc KVYO.N : Barclays raises to overweight from equal weight * NetA
A
F
G
N
R
G
D
M

U.S. STOCKS MakeMyTrip, WaFd, Bolt Biotherapeutics

BUZZ-U.S. STOCKS ON THE MOVE-MakeMyTrip, WaFd, Bolt Biotherapeutics Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The benchmark S&P 500 .SPXand the Nasdaq .IXIC touchedrecord highs on Wednesday after a lower-than-expected increase in a key inflation metric buttressed hopes that the Federal Reserve will cut interest rates this year.
B
C
G
U
U
D
G

Global Payments dips after Mizuho cuts PT

BUZZ-Global Payments dips after Mizuho cuts PT ** Shares of payments technology firm Global Payments GPN.N fall as much as 1.8%, last down 1.1% at $108.95 ** Mizuho Securities cuts GPN PT to $105 from $129, a 4.7% downside to the last close; reiterates "neutral" rating on the stock ** Brokerage says GPN shares have underperformed this year largely
G

U.S. Mastercard, Metagenomi, Ziff Davis

U.S. RESEARCH ROUNDUP- Mastercard, Metagenomi, Ziff Davis May 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Mastercard, Metagenomi and Ziff Davis, on Thursday. HIGHLIGHTS * Community Healthcare Trust Inc CHCT.N : Piper Sandler cuts to neutral from overweight * Mastercard Inc MA.N : JP Morgan cuts target price to $510 from $520 * Metagenomi Inc MGX.O : JP Morgan cuts to neutral from overweight * Parsons Corp PSN.N
A
A
C
E
M
A
A
C
A
E
G
B
C

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.